Treatment Strategies and Prognosis for Moderate Stroke Patients in China
Cerebrovascular Diseases · 2023
DOI: 10.1159/000535171 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cerebrovascular Diseases, 2023. Verfasst von Liyuan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, wlystudent@163.com. Hauptthemen laut MEDLINE: Aspirin, Clopidogrel, Dual Anti-Platelet Therapy, Ischemic Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Moderate stroke patients with National Institutes of Health Stroke Scale (NIHSS) scores of 4–10 and without intravenous thrombolysis or endovascular treatment are basically excluded from current secondary prevention trials. We aimed to explore the effectiveness of mono- versus dual-antiplatelet treatment (DAPT) strategies against subsequent stroke for these patients in a nationwide cohort.
Methods
Data were derived from the Third China National Stroke Registry (CNSR-III). In this prospective nationwide cohort, moderate ischemic stroke patients with NIHSS scores of 4–10 and without intravenous thrombolysis or endovascular treatment were included and categorized into mono- or dual-antiplatelet groups. Demographics, medical history, NIHSS score, imaging, and laboratory data were collected. The outcomes were stroke recurrence and all-cause mortality at 3 months and 1 year, respectively. Cox proportional hazards models were utilized to investigate the association of treatment strategies and prognosis.
Results
Of a total of 2,414 patients enrolled in the study, 1,633 (67.6%) received clopidogrel or aspirin, and 781 (32.4%) received DAPT. Recurrent stroke occurred in 108 (6.6%) patients of the mono-antiplatelet group and 40 (5.1%) patients of the DAPT group (adjusted hazard ratio [aHR] 0.73, 95% confidential interval [CI] 0.47–1.13, p = 0.16) at 3 months, and the rate of stroke recurrence was 10.7% in the mono-antiplatelet group and 8.6% in the DAPT group (aHR 0.81, 95% CI 0.58–1.13, p = 0.22) at 12 months. The DAPT paradigm was not significantly associated with death at 3 months (0.6% vs. 0.3%, aHR 0.28, 95% CI: 0.04–2.25) but significantly reduced the mortality at 12 months (2.3% vs. 1.0%, aHR 0.41, 95% CI: 0.17–0.98, p = 0.046).
Conclusions
In moderate stroke patients presenting within 24 h of symptom onset, the addition of clopidogrel 75 mg to aspirin might not be associated with lower risk of recurrent stroke than aspirin or clopidogrel alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, wlystudent@163.com.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
- Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Chinese Institute for Brain Research, Beijing, China.
Zitieren
APA
Wang, L., Zhou, Q., Gu, H., Hao, M., Xiong, Y., & Wang, Y. (2023). Treatment Strategies and Prognosis for Moderate Stroke Patients in China. Cerebrovascular Diseases. https://doi.org/10.1159/000535171
Vancouver
Wang L, Zhou Q, Gu H, Hao M, Xiong Y, Wang Y. Treatment Strategies and Prognosis for Moderate Stroke Patients in China. Cerebrovascular Diseases. 2023. doi:10.1159/000535171
BibTeX
@article{Wang2023,
author = {Wang, Liyuan and Zhou, Qi and Gu, Hongqiu and Hao, Manjun and Xiong, Yunyun and Wang, Yongjun},
title = {Treatment Strategies and Prognosis for Moderate Stroke Patients in China},
journal = {Cerebrovascular Diseases},
year = {2023},
doi = {10.1159/000535171}
}
EUVIMED